Skip to main content
JEONJINBIO CO., LTD. logo

JEONJINBIO CO., LTD. — Investor Relations & Filings

Ticker · 110020 ISIN · KR7110020005 KO Manufacturing
Open in API
Filings indexed 371 across all filing types
Latest filing 2023-11-29 AGM Information
Country KR South Korea
Listing KO 110020

About JEONJINBIO CO., LTD.

http://jjbious.com/01

JEONJINBIO CO., LTD. is a biotechnology company specializing in the research, development, and production of products for pest control and the mitigation of damage from nuisance animals. The company's core offerings consist of natural bio-pesticides and repellents formulated from natural materials as alternatives to conventional chemical products. Its product line includes specialized solutions for repelling birds, boars, and other animals. The company emphasizes innovation and safety, supported by its dedicated research and development center and various product certifications, including USA EPA approval for its bird repellent.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and is a '정정신고' (Correction Report). It details the agenda for an upcoming Extraordinary General Meeting, including the appointment of directors and changes to business purposes. This document serves as the official notice and proxy-related information for shareholders regarding the meeting logistics and agenda items, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2023-11-29 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the amendment of payment dates and listing dates for a third-party capital increase. This type of filing is a regulatory disclosure regarding capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2023-11-27 Korean
[기재정정]소액공모공시서류(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Small-Scale Public Offering Disclosure' (소액공모공시서류) filed by Jeonjin BioPharm. It details a capital increase through a third-party allocation of shares, including the offering price, payment dates, and investment risk factors. This type of filing is a regulatory requirement for companies raising capital below a certain threshold (1 billion KRW) without filing a full securities registration statement. In the provided taxonomy, this fits best under 'Share Issue/Capital Change' (SHA) as it pertains to the issuance of new shares and capital structure changes.
2023-11-24 Korean
[기재정정]최대주주변경을수반하는주식양수도계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Jeonjin BioPharm) regarding a 'Change in Largest Shareholder' via a stock purchase agreement. It is a formal amendment (정정신고) to a previous disclosure, detailing changes in payment schedules and share transfer amounts. This type of corporate disclosure regarding ownership structure and major shareholding changes is classified as a Regulatory Filing (RNS) in the provided schema, as it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of the entity itself) or Director's Dealing (which refers to individual insider trades).
2023-11-24 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의). It specifically details an amendment (정정신고) to a previously filed notice, updating the date of the Extraordinary General Meeting. Since this document serves as the official notice and solicitation of information for shareholders regarding an upcoming meeting, it falls under the category of Proxy Solicitation & Information Statement.
2023-11-24 Korean
[기재정정]기타경영사항(자율공시)(제8회 무기명식 이권부 무보증 사모 전환사채 취득 후 재매각의 건)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (Jeonjin BioPharm) regarding a correction to a previous disclosure about the resale of convertible bonds. It details the amendment of a payment date for a financial transaction. Since this relates to financing activities and capital structure changes (convertible bonds), it falls under the 'Capital/Financing Update' category.
2023-11-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.